Abstract
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15-20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, and IDH2R172 mutations on genomic DNA in 322 samples from 103 adult patients with primary IDH1/2 mutant acute myeloid leukemia and enrolled on Acute Leukemia French Association (ALFA) - 0701 or -0702 clinical trials. The median IDH1/2 mutant allele fraction in bone marrow samples was 42.3% (range, 8.2 - 49.9%) at diagnosis of acute myeloid leukemia, and below the detection limit of 0.2% (range, <0.2 - 39.3%) in complete remission after induction therapy. In univariate analysis, the presence of a normal karyotype, a NPM1 mutation, and an IDH1/2 mutant allele fraction <0.2% in bone marrow after induction therapy were statistically significant predictors of longer disease-free survival. In multivariate analysis, these three variables remained significantly predictive of ...Continue Reading
Citations
Apr 19, 2019·Leukemia & Lymphoma·Evgenii ShumilovUlrike Bacher
Jan 12, 2020·Metabolomics : Official Journal of the Metabolomic Society·Caroline Lo PrestiPascal Mossuz
Apr 2, 2020·Blood·Robert P HasserjianBenjamin L Ebert
Dec 7, 2019·Hematology·Sylvie D Freeman, Christopher S Hourigan
Aug 28, 2019·Cells·Isabel CastroPaula Ludovico
Aug 10, 2019·Frontiers in Oncology·Maria Teresa VosoFrancesco Buccisano
Aug 17, 2018·Neurosurgery·Yen-Ying ChenDonald Ming-Tak Ho
Dec 10, 2019·Annals of Hematology·Sabine Khalife-HachemJean-Baptiste Micol
Oct 9, 2020·JAMA Oncology·Nicholas J ShortFarhad Ravandi
Aug 30, 2020·Cancers·Ugo TestaElvira Pelosi
Dec 30, 2020·Leukemia & Lymphoma·Diego CarbonellCarolina Martínez-Laperche
Feb 12, 2021·Blood Advances·Caroline Lo PrestiPascal Mossuz
Feb 13, 2021·Frontiers in Oncology·Lok Lam NgaiJacqueline Cloos
Feb 23, 2021·British Journal of Haematology·Sanam LoghaviSa A Wang
Jun 15, 2021·British Journal of Haematology·Naranie Shanmuganathan, Susan Branford
Jun 22, 2021·PloS One·Petra KövyHajnalka Andrikovics
Aug 12, 2021·Leukemia·Luca Vincenzo CappelliAlexander Höllein